Xenon Pharmaceuticals (NASDAQ: XENE) reported Q2 EPS of ($0.41), $0.02 worse than the analyst estimate of ($0.39). Revenue for the quarter came in at $20 thousand versus the consensus estimate of $250 thousand.

For earnings history and earnings-related data on Xenon Pharmaceuticals (XENE) click here.